What is Roth Capital’s Forecast for MGRM Q1 Earnings?

Monogram Orthopaedics, Inc. (NASDAQ:MGRM) – Stock analysts at Roth Capital boosted their Q1 2025 earnings per share (EPS) estimates for shares of Monogram Orthopaedics in a report released on Thursday, March 13th. Roth Capital analyst J. Wittes now expects that the company will post earnings per share of ($0.10) for the quarter, up from their prior forecast of ($0.11). Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Monogram Orthopaedics’ current full-year earnings is ($0.49) per share. Roth Capital also issued estimates for Monogram Orthopaedics’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($0.70) EPS, Q1 2026 earnings at ($0.11) EPS, Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($0.63) EPS and FY2027 earnings at ($0.24) EPS.

Monogram Orthopaedics (NASDAQ:MGRM) last released its earnings results on Wednesday, March 12th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03.

Separately, Roth Mkm assumed coverage on Monogram Orthopaedics in a research note on Monday, December 9th. They issued a “buy” rating and a $4.00 price objective for the company.

Monogram Orthopaedics Price Performance

Shares of MGRM stock opened at $3.67 on Monday. The business has a fifty day moving average of $2.56 and a 200 day moving average of $2.49. The firm has a market capitalization of $129.51 million, a price-to-earnings ratio of -7.81 and a beta of 1.66. Monogram Orthopaedics has a 1 year low of $1.53 and a 1 year high of $4.90.

Institutional Investors Weigh In On Monogram Orthopaedics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its stake in shares of Monogram Orthopaedics by 1,267.4% in the third quarter. Geode Capital Management LLC now owns 210,144 shares of the company’s stock worth $557,000 after buying an additional 194,776 shares during the last quarter. Fiduciary Family Office LLC purchased a new stake in Monogram Orthopaedics in the 4th quarter worth approximately $70,000. Northern Trust Corp grew its stake in shares of Monogram Orthopaedics by 110.6% during the 4th quarter. Northern Trust Corp now owns 45,873 shares of the company’s stock worth $109,000 after purchasing an additional 24,088 shares during the period. State Street Corp purchased a new position in shares of Monogram Orthopaedics during the 3rd quarter valued at approximately $62,000. Finally, Orion Portfolio Solutions LLC purchased a new stake in Monogram Orthopaedics during the fourth quarter worth $31,000. 0.45% of the stock is owned by institutional investors and hedge funds.

Monogram Orthopaedics Company Profile

Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.